Rapid cerebral amyloid binding by Aβ antibodies infused into β-amyloid precursor protein transgenic mice

Biological Psychiatry

Volumn 68, Issue 10, 2010, Pages 971-974

  Winkler, David T ^a,b   Abramowski, Dorothee ^c   Danner, Simone ^c   Zurini, Mauro ^c   Paganetti, Paolo ^c   Tolnay, Markus ^b   Staufenbiel, Matthias ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; amyloid; dementia; immunotherapy; neuropsychiatry; transgenic mouse model

Indexed keywords

AMYLOID BETA PROTEIN 1 ANTIBODY; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; IMMUNOGLOBULIN G2A ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG PENETRATION; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENILE PLAQUE; SINGLE DRUG DOSE; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS;

AGE FACTORS; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFUSIONS, INTRAVENOUS; MALE; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID;

EID: 78049417919     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.01.030     Document Type: Article

References (20)

1. H.W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang Therapeutic approaches to Alzheimer's disease Brain 129 2006 2840 2855
2. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, and M. Raskind A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
3. C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, and A. Bayer Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial Lancet 372 2008 216 223
4. D.L. Brody, and D.M. Holtzman Active and passive immunotherapy for neurodegenerative disorders Annu Rev Neurosci 31 2008 175 193
5. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, and H. Grajeda Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 2000 916 919
6. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, and T. Guido Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
7. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc Natl Acad Sci U S A 98 2001 8850 8855
8. R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul, and D.M. Holtzman Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease Science 295 2002 2264 2267
9. C. Sturchler-Pierrat, D. Abramowski, M. Duke, K.H. Wiederhold, C. Mistl, and S. Rothacher Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology Proc Natl Acad Sci U S A 94 1997 13287 13292
10. S.A. Wolf, G. Kronenberg, K. Lehmann, A. Blankenship, R. Overall, and M. Staufenbiel Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease Biol Psychiatry 60 2006 1314 1323
11. M.C. Herzig, D.T. Winkler, P. Burgermeister, M. Pfeifer, E. Kohler, and S.D. Schmidt Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis Nat Neurosci 7 2004 954 960
12. G. Schrader-Fischer, and P.A. Paganetti Effect of alkalizing agents on the processing of the beta-amyloid precursor protein Brain Res 716 1996 91 100
13. D. Abramowski, K.H. Wiederhold, U. Furrer, A.L. Jaton, A. Neuenschwander, and M.J. Runser Dynamics of A{beta} turnover and deposition in different APP transgenic mouse models following gamma-secretase inhibition J Pharmacol Exp Ther 327 2008 411 424
14. R.B. DeMattos, K.R. Bales, M. Parsadanian, M.A. O'Dell, E.M. Foss, and S.M. Paul Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease J Neurochem 81 2002 229 236
15. D.T. Winkler, L. Bondolfi, M.C. Herzig, L. Jann, M.E. Calhoun, and K.H. Wiederhold Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy J Neurosci 21 2001 1619 1627
16. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746
17. Y. Levites, L.A. Smithson, R.W. Price, R.S. Dakin, B. Yuan, and M.R. Sierks Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models FASEB J 20 2006 2576 2578
18. D.R. Thakker, M.R. Weatherspoon, J. Harrison, T.E. Keene, D.S. Lane, and W.F. Kaemmerer Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice Proc Natl Acad Sci U S A 106 2009 4501 4506
19. J. Koenigsknecht-Talboo, M. Meyer-Luehmann, M. Parsadanian, M. Garcia-Alloza, M.B. Finn, and B.T. Hyman Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice J Neurosci 28 2008 14156 14164
20. K. Yamada, C. Yabuki, P. Seubert, D. Schenk, Y. Hori, and S. Ohtsuki Abeta immunotherapy: Intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta J Neurosci 29 2009 11393 11398